Blood samples may reveal why KRAS drugs fail
NCT ID NCT05272423
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study collects blood samples from up to 500 adults with KRAS G12C cancer whose current treatment has stopped working. Researchers will analyze the samples to find genetic changes that cause resistance to KRAS inhibitors like sotorasib and adagrasib. No new treatment is given; the goal is to learn why resistance happens in different cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.